{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:37:09Z","timestamp":1793900229755,"version":"4.8.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Sanofi-Genzyme"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Avacopan, a selective C5aR1 inhibitor, recently emerged as a glucocorticoid (GCs) sparing agent in anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitis (AAV). We aim to evaluate the tolerance and efficacy of avacopan given outside randomized clinical trials or with severe kidney involvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this multicentre retrospective study, we reviewed the clinical charts of patients with AAV and contraindication to high dose of GCs who received avacopan 30\u2009mg b.i.d plus standard-of-care regimen owing to the French early access program between 2020 and 2023. Efficacy and safety data were recorded using a standardized case report form.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 31 patients (median age 72\u2009years), 10 had a relapsing AAV, 20 had anti-myeloperoxidase antibodies and 30 had kidney vasculitis. Induction regimen included rituximab (n\u2009=\u200927), cyclophosphamide (n\u2009=\u20092) or both (n\u2009=\u20092). Five patients did not receive GCs. Despite rapid GCs tapering (which were withdrawn in 23 patients before month 3), 25 patients (81%) had a favourable outcome and no severe adverse event. The estimated glomerular filtration rate increased from 19 [15; 34] to 35\u2009mL\/min\/1.73\u2009m2 [23; 45] at month 12 (P &amp;lt; 0.05), independently of kidney biopsies findings. One patient developed refractory AAV and two had a relapse while receiving avacopan. At month 12, ANCA remained positive in 10\/18 patients (55.5%). Two patients developed severe adverse events leading to a withdrawal of avacopan (hepatitis and age-related macular degeneration).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The GCs\u2019 sparing effect of avacopan was confirmed, even in patients with severe kidney vasculitis, but further studies are required to identify the optimal dosing of GCs when avacopan is used.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae359","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T12:16:50Z","timestamp":1720873010000},"page":"2214-2219","source":"Crossref","is-referenced-by-count":29,"title":["Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study"],"prefix":"10.1093","volume":"64","author":[{"given":"Charlotte","family":"Gabilan","sequence":"first","affiliation":[{"name":"D\u00e9partement de N\u00e9phrologie et Transplantation d\u2019organes, Centre de R\u00e9f\u00e9rence des Maladies R\u00e9nales Rares, Centre Hospitalier Universitaire de Toulouse, French Intensive Care Renal Network , Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Belliere","sequence":"additional","affiliation":[{"name":"D\u00e9partement de N\u00e9phrologie et Transplantation d\u2019organes, Centre de R\u00e9f\u00e9rence des Maladies R\u00e9nales Rares, Centre Hospitalier Universitaire de Toulouse, French Intensive Care Renal Network , Toulouse,","place":["France"]},{"name":"Facult\u00e9 de Sant\u00e9, Universit\u00e9 Toulouse-3 , Toulouse,","place":["France"]},{"name":"INSERM U1297, Institut des Maladies Cardiovasculaires et M\u00e9taboliques, Renal Fibrosis Lab , Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-1415","authenticated-orcid":false,"given":"Olivier","family":"Moranne","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Centre Hospitalier Universitaire de N\u00eemes , N\u00eemes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Pfirmann","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation R\u00e9nale, Centre Hospitalier Universitaire de Bordeaux , Bordeaux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Samson","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Centre Hospitalier Universitaire de Dijon , Dijon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Delattre","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Centre Hospitalier de Boulogne-sur-Mer , Boulogne-sur-Mer,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Thoreau","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, H\u00f4pital Cochin, Assistance Publique\u2014H\u00f4pitaux de Paris , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gueutin","sequence":"additional","affiliation":[{"name":"Centre Universitaire des Maladies R\u00e9nales, UNICAEN, CHU de Caen Normandie, Normandie Universit\u00e9 , Caen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Boyer","sequence":"additional","affiliation":[{"name":"Centre Universitaire des Maladies R\u00e9nales, UNICAEN, CHU de Caen Normandie, Normandie Universit\u00e9 , Caen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Leurs","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Centre Hospitalier de Dunkerque , Dunkerque,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Astouati","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Centre de r\u00e9f\u00e9rence des maladies autoimmunes syst\u00e9miques rares du Nord, Nord-Ouest et M\u00e9diterran\u00e9e (CeRAINOM), U1286\u2014INFINITE, Institute for Translational Research in Inflammation , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ronsin","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation r\u00e9nale, Centre Hospitalier Universitaire de Nantes , Nantes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Quemeneur","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et M\u00e9decine Interne, Centre Hospitalier de Valenciennes , Valenciennes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ribes","sequence":"additional","affiliation":[{"name":"D\u00e9partement de N\u00e9phrologie et Transplantation d\u2019organes, Centre de R\u00e9f\u00e9rence des Maladies R\u00e9nales Rares, Centre Hospitalier Universitaire de Toulouse, French Intensive Care Renal Network , Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, H\u00f4pital Europ\u00e9en\u2014Georges Pompidou, Assistance Publique\u2014H\u00f4pitaux de Paris , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[{"name":"D\u00e9partement de N\u00e9phrologie et Transplantation d\u2019organes, Centre de R\u00e9f\u00e9rence des Maladies R\u00e9nales Rares, Centre Hospitalier Universitaire de Toulouse, French Intensive Care Renal Network , Toulouse,","place":["France"]},{"name":"Facult\u00e9 de Sant\u00e9, Universit\u00e9 Toulouse-3 , Toulouse,","place":["France"]},{"name":"INSERM U1297, Institut des Maladies Cardiovasculaires et M\u00e9taboliques, Renal Fibrosis Lab , Toulouse,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"key":"2025040212103745000_keae359-B1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025040212103745000_keae359-B2","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025040212103745000_keae359-B3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2025040212103745000_keae359-B4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025040212103745000_keae359-B5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.ekir.2023.05.017","article-title":"Avacopan in patients with rapidly progressive glomerulonephritis requiring dialysis","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025040212103745000_keae359-B6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","article-title":"Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"van Leeuwen","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025040212103745000_keae359-B7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ekir.2022.01.1065","article-title":"Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option","volume":"7","author":"Gabilan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025040212103745000_keae359-B8","doi-asserted-by":"crossref","first-page":"E2243799","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis","volume":"5","author":"Pu\u00e9chal","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025040212103745000_keae359-B9","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"2025040212103745000_keae359-B10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2025040212103745000_keae359-B11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.kint.2023.10.009","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int"},{"key":"2025040212103745000_keae359-B12","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/rheumatology\/kead087","article-title":"CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum","volume":"62","author":"Turgeon","year":"2023","journal-title":"Rheumatology"},{"key":"2025040212103745000_keae359-B13","first-page":"1783","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume-title":"Clin Res","author":"Zonozi","year":"2024"},{"key":"2025040212103745000_keae359-B14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025040212103745000_keae359-B15","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2025040212103745000_keae359-B16","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1093\/rheumatology\/kead561","article-title":"Comment on: a case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Shirota","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212103745000_keae359-B17","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/rheumatology\/kead285","article-title":"A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212103745000_keae359-B18","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/rheumatology\/kead509","article-title":"Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan","volume":"63","author":"Kojima","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025040212103745000_keae359-B19","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1016\/j.cell.2023.04.031","article-title":"C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection","volume":"186","author":"Desai","year":"2023","journal-title":"Cell"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae359\/58588962\/keae359.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/2214\/58588962\/keae359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/2214\/58588962\/keae359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:41:59Z","timestamp":1743612119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/2214\/7713282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,13]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae359","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,7,13]]}}}